Fig. 2From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysisChoroidal neovascularization conversion in the fellow eye. The percentage of patients that converted to CNV in the fellow eye in the current study and other studies: Barbazetto et al. [41] for ANCHOR, MARINA and PDT photodynamic therapy with verteporfin, Overall numbers from a meta-analysis (Wong et al. Ophthalmology 2008;115:1524), AREDS Age-Related Eye Disease Study [19], TT triple combination therapy in current study, TTZ triple combination therapy with zeaxanthin in current study (CNV choroidal neovascularization). A 24-month comparison of conversion rates to CNV in the fellow eye in the TT and TTZ cohorts showed that zeaxanthin significantly decreased conversion in fellow eyes (p = 0.03). A 24-month MARINA and ANCHOR CNV conversion study in the fellow eye revealed a far greater 24-month rate in MARNA/ANCHOR than in our triple combination therapy cohort (p = 0.6 × 10−6) or the triple combination therapy cohort with zeaxanthin (p = 1.0 × 10−14)Back to article page